Psilocybin Compared With LSD, DMT and Mescaline

When people discuss psychedelics, they are often referring to a specific family of compounds known as the classic serotonergic psychedelics: psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and mescaline. In scientific literature, these substances are grouped together because they share a primary mechanism of action in the brain. Despite this common neurological thread, they differ wildly in where they come from, how long their effects last, and how they have been used historically. In South Africa, all four of these substances are currently classified as Schedule 7 controlled substances under the Medicines and Related Substances Act, making their use, possession, or distribution strictly illegal outside of highly restricted research environments.

Origins: Fungi, Cacti, and the Laboratory

The origins of these compounds span nature and modern chemistry. Psilocybin occurs naturally in over 200 species of fungi, predominantly found in tropical and subtropical regions. Mescaline is another naturally occurring compound, found in several cacti native to the Americas, such as peyote and the San Pedro cactus. DMT is structurally a simple analogue of serotonin and is found in a variety of plants, as well as being synthesised in laboratory settings for research.

LSD, by contrast, is a semi-synthetic substance. It was originally derived from ergotamine, a chemical produced by the ergot fungus that infects rye, and its profound psychoactive properties were discovered in the mid-20th century. These diverse origins have shaped their cultural histories: psilocybin, mescaline, and DMT have deep, centuries-old roots in Indigenous spiritual and healing ceremonies, whereas LSD emerged entirely from 20th-century pharmaceutical chemistry before becoming a countercultural icon.

Duration: A Spectrum of Pharmacokinetics

A key distinction among these compounds is their duration of action, which is governed by how the body metabolises them. DMT is famously rapid in its onset and short in its duration; when inhaled, its effects often last only a matter of minutes. However, when DMT is consumed orally alongside a monoamine oxidase inhibitor—as in the traditional Amazonian brew ayahuasca—the body's metabolism is altered, extending the experience to several hours. Psilocybin generally lasts between four and six hours. LSD is considerably longer, with effects often lasting eight to twelve hours. Mescaline is similarly long-lasting, sometimes exceeding twelve hours.

These differences in duration have significant practical implications for clinical research. A shorter-acting compound like psilocybin is often more manageable in a therapeutic setting, allowing for supervised sessions to fit within a standard clinical workday. Conversely, an LSD or mescaline session requires a substantially longer commitment of medical staff time and clinical resources, which can complicate the design of therapeutic trials.

The Common Neurological Thread

Despite their differences in origin and duration, the classic psychedelics share a fundamental pharmacological trait: they act primarily as agonists at the serotonin 2A (5-HT2A) receptor in the brain. Research from institutions such as the Imperial College London Centre for Psychedelic Research suggests that this receptor interaction is the primary driver of the characteristic subjective effects of these substances, including altered perception and changes in cognition. However, they do not all bind to the receptor in exactly the same way. LSD, for example, tends to bind with high affinity to multiple receptor subtypes, which researchers believe may contribute to its distinct subjective profile compared to psilocybin or DMT. Neuroimaging studies generally show that all classic psychedelics disrupt the default mode network—a brain network associated with introspection and the sense of self—though the precise temporal dynamics of these changes vary alongside the duration of the substance.

Legal Status and Policy Implications in South Africa

From a regulatory perspective, South Africa treats these four substances identically. The South African Health Products Regulatory Authority (SAHPRA) classifies psilocybin, LSD, DMT, and mescaline as Schedule 7 substances under the Medicines and Related Substances Act. This is the most restrictive category, reserved for drugs with a high potential for harm and no accepted medical use. This classification places them alongside substances like heroin and ignores the emerging, albeit early, clinical evidence regarding their potential therapeutic applications.

Internationally, some regulators are beginning to differentiate these compounds based on evidence. For example, the Therapeutic Goods Administration (TGA) in Australia recently rescheduled psilocybin for restricted medical use in treatment-resistant depression, while leaving LSD and mescaline in their most restricted categories. As global research continues, drug policy reform advocates argue that South African law may eventually need to adopt a more evidence-based, nuanced approach to scheduling—one that differentiates between these compounds based on their actual pharmacological profiles and therapeutic potential, rather than applying a blanket prohibition rooted in mid-20th-century international drug treaties.